The Application Progress of Tumor Microenvironment-Responsive Drug Carriers in Precision Chemotherapy

Authors

  • Jingtong Liang

DOI:

https://doi.org/10.61173/hv714419

Keywords:

Drug therapy, tumor microenvironment, re-sponsive carriers

Abstract

Drug therapy is a necessary means of treating malignant tumors. By taking or injecting drugs, it effectively inhibits or reduces the number of tumor cells in the body and controls the metastasis of tumor cells. However, drug therapy may resultin a series of side effects during the treatment process, such as hair loss and liver function damage, which aggravates the treatment pain of patients. In recent years, researchers have proposed a type of responsive drug carrier based on the tumor microenvironment (TME) cells in response to the differences between the extracellular environment of tumor cells and that of normal cells, in order to improve therapeutic targeting and reduce therapeutic side effects. This article focuses on the differences in pH value, REDOX substance concentration and enzyme expression between tumor cells and normal somatic cells in the TME, explores the differences among different indicators and the mechanism of designing responsive carriers. Meanwhile, taking an experimental model of delivering curcumin based on a pH-temperature combined responsive polymer carrier as an example, the feasibility of targeted release is analyzed. Meanwhile, due to the high heterogeneity of human cancer cells, the possible errors and limitations of the experimental model are evaluated. In addition, the prospects of artificial intelligence-assisted personalized drug carriers are discussed in a multivariate manner based on the TME.

References

[1] Maleki H, Aiyelabegan T H, Javadi P, et al. Nanotechnologymediated precision drug delivery strategies for breast cancer treatment[J]. Biomedicine & Pharmacotherapy, 2025, 188: 118224.

[2] Rajankar N, Kumar A, Gulbake A. Navigating tumor microenvironment with TME-responsive nanocarriers: Strategies for targeted drug delivery in solid tumor[J]. Journal of Drug Delivery Science and Technology, 2025, 110: 107050.

[3] Deng B, Dai H, Zhu M Y, et al. Research Progress of Enzyme-Sensitive dual-responsive Polymer Nanocarriers in Anti-tumor Therapy[J]. Guangzhou Chemical Industry, 2024, 52(24): 5–7+12.

[4] Ellah A S H, Zhao D, Zhou Y, et al. Unlocking pH-responsive dual payload release through hydrazone linkage chemistry[J]. Bioorganic & Medicinal Chemistry, 2025, 123: 118172.

[5] Koscielniak P, Sawicka M, Sterin I, et al. Cystaminecrosslinked and nanozyme decorated polyacrylic acid-based composite microgel of dual functionality: delivery and controlled doxorubicin release[J]. Applied Surface Science Advances, 2025, 2: 100773.

[6] Su X, Aprahamian I. Hydrazone-based switches, metalloassemblies and sensors[J]. Chemical Society Reviews, 2014, 43(6): 1963–1981. Dean&Francis Jingtong Liang1,*

[7] Bai J W. Application of Responsive Nanomaterials in Regulating the Tumor Microenvironment and Tumor Therapy[D]. Lanzhou: Lanzhou University, 2024. DOI:10.27204/d.cnki. glzhu.2024.000408.

[8] Xie J H. Reduction-sensitive Polyurethane Nanomedicine Carriers Based on Tumor Microenvironment Response[D]. Wuhan: Wuhan University of Technology, 2023. DOI:10.27381/ d.cnki.gwlgu.2023.000735.

[9] Xu X, Saw P E, Tao W, et al. ROS-Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy[J]. Advanced Materials, 2017, 29(33): 1700141.

[10] Zhang S. Preparation and Properties Research of Stimulus- Responsive Nanomedicine Carriers[D]. Changchun: Jilin University, 2023. DOI:10.27162/d.cnki.gjlin.2023.006948.

[11] Badparvar F, Marjani A P, Salehi R, et al. Dual pH/redoxresponsive hyperbranched polymeric nanocarriers with TME- trigger size shrinkage and charge reversible ability for amplified chemotherapy of breast cancer[J]. Scientific Reports, 2024, 14: 8567.

[12] Wang T, Wang F Q, Sun M J, et al. Gastric environmentstable oral nanocarriers for in situ colorectal cancer therapy[J]. International Journal of Biological Macromolecules, 2019, 139: 1035–1045.

[13] Luo R, Yue Z, Yang Q, et al. In situ repolarization of tumorassociated macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy[J]. Journal of Pharmaceutical Analysis, 2024, 14: 100941.

[14] Hassan B A R, Mohammed A H, Hallit S, et al. Exploring the role of artificial intelligence in chemotherapy development, cancer diagnosis, and treatment: present achievements and future outlook[J]. Frontiers in Oncology, 2025, 15: 1475893.

Downloads

Published

2025-08-26